China Medical System Once Again Received MSCI-ESG ‘AA’ Rating, Leading the Industry in ESG Management

SHENZHEN, CHINA, Jul 31, 2023 – (ACN Newswire) – Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.

MSCI is one of the most widely used, influential, and referenced rating companies in the global market. Based on a scientifically rigorous evaluation system, it evaluates companies' risk control performance and sustainable development potential comprehensively from various aspects such as environment, human capital, health accessibility, product safety and quality, and corporate governance. MSCI-ESG rating results have been regarded by global investors as an important non-financial basis for investment decision-making. Being back to the "AA" rating, reflects the full recognition of the Group's ESG management practices by the international authoritative rating company.

The Group deeply integrates the concept of sustainable development into its operations with a development perspective, continuously improves its internal governance under the guidance of its ESG strategy, and actively assumes its responsibilities as a corporate citizen. Based on years of continuous investment in sustainable development, CMS's ESG management has been widely recognized: over the past three years, the Group's MSCI-ESG rating has maintained an "A" or "AA; its S&P Global ESG score surpassed 92% of the global peers with a score of 53, and successfully stood out from approximately 1,600 Chinese companies to be included in the first "Sustainability Yearbook (China)" of S&P Global.

In the future, CMS will always keep in mind its mission of being a responsible citizen, and work together with its stakeholders to promote healthy, harmonious, and sustainable development of the industry, society, and environment.

About CMS:

CMS (0867.HK) is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet healthcare needs.

CMS focuses on developing first- or best-in-class innovative products and has made the layout of 30 differentiated pipeline products with strong market potential. CMS deeply engages in specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to strengthen the competitiveness of its cardio-cerebrovascular/gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business, whilst enhancing the scale and efficiency. CMS also entered into the Southeast Asian market to create new opportunities to further enhance the sustainable development of the Group.

Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avantor Inaugurates Expanded Singapore Hub

One-Stop Facility with cGMP Manufacturing to Bolster AMEA’s Biopharma Industry

SINGAPORE, July 11, 2023 – (ACN Newswire) – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies, and applied materials industries, today inaugurated its expanded Singapore Hub which includes newly added cGMP manufacturing and a world class quality control laboratory. The hub is a one-stop facility serving the needs of customers across Asia, Middle East, and Africa (AMEA), strengthening the region’s innovation and biopharma ecosystems.

Avantor today officially inaugurated its expanded Singapore Manufacturing & Distribution Hub. Standing from left to right: Christophe Couturier (EVP, Asia Middle East Africa, Avantor), Elaine Teo (SVP & Head, Investment Facilitation, Singapore EDB) and Narayana Rao Rapolu (VP, Biopharma, Asia Middle East Africa, Avantor).

*Avantor’s expanded Singapore Hub to bolster Asia Pacific’s Biopharma ecosystem with enhanced manufacturing and distribution.*

Strategically located in Singapore, the hub enables quicker turnaround times and expedites customers’ access to raw materials that are essential in AMEA’s drug discovery and development whilst upholding stringent quality standards.

“At Avantor, we recognize the growing complexities around customer requirements and regulatory standards across AMEA’s biopharma industry,” said Christophe Couturier, Executive Vice President, AMEA. “By enhancing our regional capabilities through the launch of our Singapore Manufacturing and Distribution Hub, we tap into our legacy of serving the evolving needs of customers, demonstrating our commitment to advancing life-changing science.”

The inauguration ceremony today was officiated by Avantor executives, Christophe Couturier, and Narayana Rao, Vice President, Biopharma – AMEA, and the Singapore Economic Development Board (EDB), represented by Elaine Teo, Senior Vice President and Head, Investment Facilitation at EDB.

“Avantor’s latest expansion of its Singapore hub enhances the supply of key materials and services required by biopharma manufacturers in Singapore and the region. This strengthens supply chain resilience for businesses and enhances the competitiveness of Singapore’s biomedical sciences industry, an integral part of Singapore’s manufacturing sector. Avantor’s successive investments in Singapore demonstrate confidence in our manufacturing and supply chain capabilities. These expansions are in line with EDB’s commitment to work with businesses to deepen their footprint and create new job opportunities in Singapore,” said Elaine Teo, Senior Vice President, EDB.

Building onto Avantor’s 2022 investment, the integration of the current distribution hub with new manufacturing operations features cGMP suites, quality testing, warehousing of certified products, batch-to-batch traceability and customized palletization capabilities. These state-of-the-art facilities allow the hub to drive innovation and efficiency to address the immediate challenges in AMEA’s biopharma industry.

About Avantor

Avantor^®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, visit avantorsciences.com and find us on LinkedIn, Twitter and Facebook.

Regional Media Contact
Christina Koh
Director – Communications AMEA
Avantor
65-9720 0169
Christina.Koh@avantorsciences.com

China Medical System Included in the First ‘Sustainability Yearbook (China)’ of S&P Global

l CMS was included into the first “Sustainability Yearbook (China)” published by S&P Global.

l Nearly 1600 Chinese companies were included in the selection pool, but only 88 companies, including CMS, were finally selected!

SHENZHEN, CHINA, June 29, 2023 – (ACN Newswire) – Recently, S&P Global, the world’s leading corporate sustainability assessment institution, has officially released the first “Sustainability Yearbook 2023 (China)”. China Medical System Holdings Limited (“CMS” or the “Group”), standing out from many outstanding companies, was successfully included in this Yearbook. Previously, S&P Global updated CMS’s Sustainability Score to 53, surpassing 92% of the global peers participating in this evaluation, and it is significantly ahead of the industry average.

S&P Global has published global versions of the “Sustainability Yearbook” for 16 consecutive years, and has received extensive attention and recognition. This year, S&P Global published the “Sustainability Yearbook (China)” for the first time, aiming to identify and recognize Chinese companies that have great sustainable development performance in different industries. Nearly 1600 Chinese companies from 60 industries were included in the selection pool of the yearbook, but only companies that scored within the top 15% of their industries and achieved a S&P Global Sustainability Score within 30% of their industry’s top-performing company can be selected. 88 companies, including CMS, were finally selected into the “Sustainability Yearbook 2023(China)”.

CMS adheres to the concept of sustainable development, and has always paid close attention to the global ESG management trends and outstanding ESG related practices, continued to optimize its internal management, and unceasingly promoted the deep integration of ESG concepts and its operation strategy. In 2022, CMS responded to the Sustainable Development Goals (SDGs) of United Nations, further optimizing the Group’s sustainable development strategy and long-term goals to lead the healthy and sustainable development of CMS.

CMS has always enthusiastically participated in public welfare activities, and actively responded to social needs with practical actions. At the same time, it strives to fulfill its responsibilities and missions of being a corporate citizen in pharmaceutical industry. CMS focuses on unmet clinical needs, and continuously brings differentiated, high-quality, affordable innovative products to patients. In the first half of 2023, three innovative products of CMS were successfully approved for marketing in China, bringing benefits to patients. In the meantime, CMS continues to create a green, clean, friendly and inclusive corporate culture and operating environment through constant improvement of its internal policies, organizational structures and training systems. Looking into the future, CMS will uphold its original aspiration to promote the harmonious development of its operations, the environment and society with long-termism, and to contribute “CMS strength” to the global sustainable development.

About CMS：

CMS focuses on developing first- or best-in-class innovative products and has made the layout of 30 differentiated pipeline products with strong market potential. CMS deeply engages in specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to strengthen the competitiveness of its cardio-cerebrovascular/gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business, whilst enhancing the scale and efficiency. CMS also entered into the Southeast Asian market to create new opportunities to further enhance the sustainable development of the Group.

Media Contact

Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

China Medical System: The first ‘Diazepam Nasal Spray’ Approved for Marketing in China

l CMS is pleased to announce the NDA of the first Diazepam Nasal Spray has been approved for marketing in China. The Product can meet current clinical needs for accessible and convenient treatment option of domestic epilepsy patients 6 years of age and older with seizure clusters/acute repetitive seizures. The Product can be administered at anytime and anywhere, and has the differentiated advantage of seizure rescue, with the characteristic of convenience and optimization through intranasal administration

l The Product’s formulation incorporates a unique combination of Vitamin E-based solvents and Intravail^® absorption enhancer, and the Product has high bioavailability, outstanding absorbability, tolerance and reliability

l In 2023, CMS’s innovation development is stepping into a new cycle of harvesting, and the Product is CMS’s third innovative drug approved for marketing in China this year

SHENZHEN, CHINA, June 12, 2023 – (ACN Newswire) – On June 12, China Medical System Holdings Limited (“CMS” or the “Group”) announced that on June 7 2023, the New Drug Application (NDA) of Diazepam Nasal Spray (the “Product”) received approval from the National Medical Products Administration of China (NMPA). The Product is the first diazepam nasal spray in China, and it is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.

The Product is a proprietary formulation of diazepam administered through the nasal mucosa, and has high bioavailability, outstanding absorbability, tolerance and reliability. Product formulation incorporates a combination of Vitamin E-based solvents and Intravail^® absorption enhancer. Intravail^® transmucosal absorption enhancement technology enables the non-invasive delivery of a broad range of proteins, peptides and small-molecule drugs.

The results of the Product’s US related clinical trial showed that 87% of seizure cluster episodes used a single dose of the Product over a 24-hour period. A post hoc analysis of these data showed the Product had a rapid onset of action with the median time from administration of the Product to seizure cessation of 4 minutes. Further analyses showed using the Product as intermittent rescue therapy significantly improves the quality of life of epileptic patients and may reflect a beneficial effect in increasing time between seizure clusters. In 2020, the Product was approved for marketing in the United States of America.

The active pharmaceutical ingredient of the Product is Diazepam, belonging to the class of benzodiazepines, which are the first-choice drugs for the treatment of seizure clusters. However, there has been a lack of drugs for the treatment of seizure clusters in the China. The Product is the first drug approved in China for the treatment of seizure clusters. It can be administered intranasally at the appropriate time by patients or their caregivers under prescription from a doctor and guidance from medical staff. The Product can meet current clinical needs for accessible and convenient treatment option of domestic epilepsy patients with seizure clusters. The Product can be administered anytime and anywhere, and has the differentiated advantage of seizure rescue, with the characteristic of convenience and optimization through intranasal administration.

CMS has always focused on unmet clinical needs, and joined hands with global innovation forces to build a pharmaceutical innovation ecosystem in an open and collaborative setting, to continuously develop differentiated innovative products for patients. Starting from 2023, CMS’s innovation development is stepping into a new cycle of harvesting. Diazepam Nasal Spray is CMS’s third innovative drug approved for marketing in China this year, following the approval of Methotrexate Injection and Tildrakizumab Injection. CMS will steadily prepare for the commercialization of innovative products to benefit more patients in China as soon as possible.

Seizure Clusters/Acute Repetitive Seizures

According to the clinical diagnosis and treatment guidelines epilepsy volume (revision in 2023), seizure clusters/acute repetitive seizures are defined as ≥3 seizures/24h for adults, ≥3 seizures/12h for children, ≤8h between each seizures, and the consciousness returning to normal level between the two seizures. Seizure clusters are common in certain epilepsy syndromes, menstrual seizures, and drug-refractory epilepsy. If not treated in time, some will develop into status epilepticus, endangering the lives of patients.

According to estimation, there are about 6.4 million active epilepsy patients in China, and about 0.3 million new cases reported each year. However, due to a lack of proper awareness towards epilepsy and limited medical resources, the current treatment gap for patients with active epilepsy in China is 49.8%, based on which it is estimated that about 3 million patients with active epilepsy in China have not received appropriate treatment. At present, there is still a lack of epidemiological research on seizure clusters in China. According to overseas studies, the rate of outpatient incidence of seizure clusters is about 15% and therefore it is estimated that nearly 500,000 patients with active epilepsy receiving regular treatment still have seizure clusters.

For further detailed information regarding Diazepam Nasal Spray, please see the following link for “Voluntary and Business Update Announcement: New Drug Application of Diazepam Nasal Spray Approved in China” issued by CMS on June 12, 2023: https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0612/2023061200453.pdf

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet healthcare needs. In 2022, the Group recorded a turnover of RMB9,150 million; in the case that all medicines were directly sold by the Group, the turnover reached RMB10,498 million. Profit for the year reached RMB3,276 million.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease

Houston, TX, Jun 8, 2023 – (ACN Newswire) – Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance Treg function, including biologics, today reported additional biomarker and brain imaging results from an open-label proof-of-concept clinical study for COYA 301 in patients with mild to moderate AD. Results of the study will be presented June 7th, 2023, at the LD Micro Conference in Los Angeles, CA. The clinical study data can be viewed here.

Highlights:
– Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines — Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) — which correlated with lack of cognitive decline of the patients over the course of the study.
– TNF-α is one of the main inflammatory cytokines involved in initiating and propagating an inflammatory response and its role in the pathophysiology of AD has been documented. The proinflammatory cytokines IL-6 and IL-1β have also been documented to play a central role in AD and in the development of neuroinflammation and induction of neuronal damage.
– Furthermore, Coya reports a case study of a patient in the COYA 301 trial who had pre-treatment and post-treatment Positron Emission Tomography (PET) brain scans to evaluate neuroinflammation. Meaningful reductions in neuroinflammation were observed throughout the cerebral cortex including hippocampal regions following treatment with COYA 301, which correlated with improvement in cognitive function in this patient.
– Coya previously reported that patients in the COYA 301 trial achieved a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE) and no cognitive decline when measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and the Clinical Dementia Rating-Sum of Boxes scale (CDR-SB).
– Coya also previously reported that treatment with COYA 301 restored peripheral Treg function and numbers, significantly lowered the levels of systemic chemokines CCL11, CCL2, and cytokine IL-15, and was well tolerated.
– An ongoing academic phase 2 double blind randomized trial (supported by the Gates Foundation and Alzheimer's Association) for use of low dose IL-2 in up to 46 mild to moderate AD patients that is underway at Houston Methodist (led by Alireza Faridar M.D. and the Chair of Coya's SAB, Stanley Appel, M.D.), should report top line data in Q2 2024, and inform Coya on its strategy.

The open-label study enrolled 8 patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25. The patients were treated with five day-courses of COYA 301 for four monthly cycles and were followed for two months post-treatment. Treg function and numbers, serum biomarkers of inflammation, and cognitive functioning as measured by the ADAS-Cog, CDR-SB and MMSE assessment tools were evaluated.

Clinically, evaluation of cognitive function showed that administration of COYA 301 resulted in a statistically significant improvement in mean MMSE scores during the treatment phase, compared to mean MMSE score at baseline (p=0.015). Consistent with the positive trend in MMSE score, mean scores in ADAS-Cog and CDR-SB scales did not significantly change at the end of treatment with COYA 301, compared to pre-treatment baseline scores, indicating no cognitive decline as measured by these validated instruments.

In addition to COYA 301 administration resulting in a statistically significant reduction of blood biomarkers CCL11, CCL2, and IL-15. Today, we report statistically significant reductions in the peripheral expression of the pro-inflammatory cytokines TNF-α, IL-6, and IL-1β. These biomarkers are well characterized in playing a central role in AD pathophysiology, propagation of neuroinflammation, and contribution to neuronal damage. The consistent reduction of these cytokines correlated with lack of cognitive decline of the patients over the course of the study. Further, the significant reduction of proinflammatory cytokine expression and the lack of clinical decline also correlated with significant increase of regulatory T cell function following the administration of COYA 301.

One of the patients in the study underwent a pre- and post-treatment PET brain scan using a radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation. Increased binding of TSPO to activated microglia in brain regions is indicative of heightened inflammation and be observed with a color code with red, orange, and yellow. In contrast, images in green and blue indicate lower levels of neuroinflammation. In this patient, the pre-treatment PET scan showed high levels of TSPO binding indicative of inflammation throughout the cerebral cortex in both sagittal and coronal views, including in hippocampal regions. The PET scan after the last cycle of COYA 301 showed marked reduction in TSPO binding across the brain representing lowered inflammation. This reduction in inflammation corresponded to improvement in cognitive function as measured by MMSE scores in this patient with AD.

"We believe these additional data further support our Treg-focused approach to develop safe and effective treatments for neurodegenerative diseases of high unmet need. We remain excited about the outcome of our studies with COYA 301 in AD and COYA 302 in ALS, and look forward to the next steps in progressing these programs," Howard H Berman, Ph.D., founder and Chief Executive Officer of Coya commented.

About Alzheimer's Disease

Alzheimer's disease is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for up to 80% of dementia cases, affecting an estimated 5.7 million Americans. In more than 90% of people with Alzheimer's, symptoms do not appear until after age 60. The incidence of the disease increases with age and doubles every 5 years beyond age 65. Alzheimer's is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer's, individuals lose the ability to carry on a conversation and respond to their environment. It is the sixth leading cause of death among all adults and the fifth leading cause for those aged 65 or older. On average, a person with Alzheimer's lives 4 to 8 years after diagnosis but can live as long as 20 years, depending on other factors. (1),(2)

References
(1) Alzheimer's Association (www.alz.org).
(2) Centers for Disease Control and Prevention (www.cdc.gov).

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's lead therapeutic programs includes Treg-enhancing biologics (COYA 300 Series product candidates) COYA 301 and COYA 302, which are intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. For more information about Coya, please visit www.coyatherapeutics.com.

Contact:
Howard Berman, CEO
Email: Howard@covatherapeutics.com
Phone: +18327786285

Forward-Looking Statements
This press release contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

China Medical System: An Innovative Drug, ILUMETRI ‘Tildrakizumab Injection’ Approved for Marketing in China

SHENZHEN, CHINA, May 30, 2023 – (ACN Newswire) – On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

– CMS is pleased to announce the NDA of Tildrakizumab Injection under the brand name of ILUMETRI, a monoclonal antibody specifically targeting the p19 subunit of IL-23, has been approved in China. ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
– The extended study of ILUMETRI's Phase III clinical trial in China, demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over treatment time. The PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3% at week 52, and ILUMETRI showed good long-term safety and tolerance.
– ILUMETRI only needs to be administered 4 times a year during maintenance treatment period, which may bring higher patient compliance.
– ILUMETRI will synergize with CMS Aesthetics' marketed products, Hirudoid, Aethoxysklerol and pipeline products, to solidify comprehensive competitiveness of CMS in the dermatology field.
– This is CMS's second innovative drug approved for marketing in China this year following the approval of Methotrexate Injection.

ILUMETRI is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMETRI has patents on composition and formulation in China.

The results of the extended study of its Phase III clinical trial in China demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over treatment time. The PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3% at week 52, and ILUMETRI showed good long-term safety and tolerance. ILUMETRI only needs to be administered 4 times a year during maintenance treatment period, which may bring higher patient compliance.

Psoriasis is an autoimmune disease with complex causes, where IL-23 is regarded as one of the important driving factors of the pathogenesis of psoriasis. The incidence of psoriasis in China is about 0.47%, with the number of patients exceeding 7 million, of which more than 30% have developed into moderate-to-severe disease. ILUMETRI will provide moderate-to-severe plaque psoriasis patients with a safe and effective treatment option.

It took only 14 months from obtaining the approval for the drug clinical trial to submitting the NDA for ILUMETRI in China, with the enrollment of 220 subjects completed in only 2.5 months (which included the Spring Festival), highlighting CMS's highly efficient clinical development capabilities supported by its commercialization strength.

ILUMETRI is CMS's second innovative drug approved to be marketed in China in 2023, following the recent approval of Methotrexate Injection. CMS has invested in, and collaborated with, innovative companies globally over the last 5 years to jointly develop innovative products with academic value and differentiated advantages, in order to meet unmet clinical needs and enhance the accessibility of global innovative drugs for Chinese patients. Starting from 2023, CMS's innovation development is stepping into the harvest period.

ILUMETRI has been approved for marketing in the Hong Kong Special Administrative Region of China in April 2022. Tildrakizumab Injection has also been approved for marketing in the U.S., EU, Japan, UK, Switzerland, Canada, Australia and other countries/regions.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet healthcare needs. In 2022, the Group recorded a turnover of RMB9,150 million; in the case that all medicines were directly sold by the Group, the turnover reached RMB10,498 million. Profit for the year reached RMB3,276 million.

CMS focuses on developing first- or best-in-class innovative products and has made the layout of 30 differentiated pipeline products with strong market potential. CMS deeply engages in specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to strengthen the competitiveness of its cardio-cerebrovascular/gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business, whilst enhancing the scale and efficiency. CMS also entered into the Southeast Asian market to create new opportunities to further enhance the sustainable development of the Group.

Media Contact
CMS Investor Relations
China Medical System Holdings Ltd.
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source: China Medical System Holdings Ltd.

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Record-breaking success at analytica Vietnam 2023. Return of the event draws largest ever crowd of attendees and participants

analytica Vietnam closes with an increase of 27% in visitor-ship, totalling 4802 unique buyers from 33 countries attending over the 3 days.
The event hosted 582 conference delegates, plus tailored laboratory tours, and exhibitor forum workshops on the show floor.
analytica Vietnam re-establishes its standing as the optimal one-stop-shop for analysis, diagnostic, laboratory and biotech professionals in the Vietnam and ASEAN market.

Ho Chi Minh, Vietnam, Apr 28, 2023 – (ACN Newswire) – Messe München announces the successful conclusion of analytica Vietnam 2023, the premier international trade fair for laboratory technology, analysis, biotechnology, and diagnostics held in Vietnam last week. The tradeshow and congress all together drew in 5384 industry professionals globally as well as over 200 international companies and brands filling the exhibition hall. The results have conclusively reflected analytica Vietnam as the ultimate platform for showcasing the latest advancements in the industry and fostering meaningful collaborations among key players in the field. The event saw unprecedented success with the largest ever edition of analytica Vietnam, featuring a 10% increase in exhibition space, with country pavilions from Germany, China, Singapore, Korea and Vietnam.

The three-day event was a hub of activity, with exhibits showcasing the latest technologies, a world-class conference program featuring over 30 conference sessions and panel discussions focussing on solutions to the latest challenges facing the industry and research findings presented by industry experts, pre-event laboratory tours, exhibitor forum, buyer-seller programs, networking nights, and hosted buyer delegations from Laos, Cambodia, and Vietnam. The event kicked off its Opening Ceremony with presence from Minister Bộ trưởng Huỳnh Thành Đạt and Vice Minister Thứ trưởng Lê Xuân Định from the Ministry of Science and Technology (MOST) in Vietnam. Attendees had the opportunity to learn, network, and reconnect with confirmed exhibitors, international pavilions, and key industry leaders, all free of charge.

As the first face-to-face meeting for the industry since the impact of COVID-19, analytica Vietnam 2023 welcomed sponsorship from industry giants such as Thermo Fisher, BIOVIA, and BTG, and brought together a spectacular reunion of the science and research sector.

The exhibition featured national and international industry leaders, including Thermo Fisher Scientific, Shimadzu, Merck, Leco, ITS, DKSH, 2H Instruments, Scilab, Eppendorf, and Waters. International exhibitors from countries such as Germany, Italy, UK, Japan, Canada, Korea, France, Czech Republic, USA, Singapore, India, Thailand, and China also showcased their latest innovations. The German Federal Ministry for Economic Affairs and Climate Action and the Association of Small & Medium Enterprises Singapore (ASME) supported the exhibition with their respective pavilions. The exhibitors expressed satisfaction with the event with Sho-Wen Yeo, Vice President and General Manager, Southeast Asia & Taiwan of Thermo Fisher Scientific stating “Our key areas are biopharma, clean energy, food safety, and research innovations so the opportunities presented in analytica Vietnam 2023 very much align with what we are focusing on, which is a great match.”

“The success of analytica Vietnam 2023 exceeded our expectations, and we are thrilled to have welcomed leading professionals and companies from the laboratory technology, analysis, and biotechnology industries,” said Mr. Michael Wilton, CEO & Managing Director of MMI Asia Pte Ltd, organiser of the exhibition and a subsidiary of Messe München GmbH. “The event provided unparalleled opportunities for networking, learning, and discovering the latest products and technologies in the industry.”

The Vietnamese government and Messe München have been at the forefront of industry development in Vietnam, and analytica Vietnam has been the perfect platform to support the further development of the industry in the country, facilitate know-how transfer, and promote investment in laboratory and biotechnology, according to Armin Wittmann, Project Director at Messe München GmbH.

As the organizer of analytica Vietnam, MMI Asia takes pride in hosting a successful event that facilitated knowledge exchange, networking, and business opportunities for all participants. The event provided a unique platform for stakeholders to connect, collaborate, and stay updated with the latest industry trends.

The impressive gathering at analytica Vietnam 2023 underscores the increasing demand for laboratory technology, analysis, and biotechnology solutions in the region, and the event has set the stage for further advancements in the industry. As the most significant gathering of professionals in Southeast Asia, analytica Vietnam continues to play a pivotal role in driving innovation, promoting investment, and facilitating knowledge exchange in the laboratory and biotechnology sectors. Plans are already underway for the next edition of analytica Vietnam, scheduled to be held on April 2-4 2025, at Saigon Exhibition and Convention Center in Ho Chi Minh, Vietnam, which is set to be even bigger and better, building on the success of this year’s event.

For more information, please visit: www.analyticavietnam.com

analytica Vietnam Main Conference

The analytica Vietnam Conference, took place parallel to the trade fair, featured over 30 conference lectures presented by national and international experts from the science and research sector across the globe. Topics covered included biomedical and forensic analysis, novel analytical methods, food analysis, environment analysis, and quality control. The conference was organized by Prof. Dr. Oliver J. Schmitz from the University of Duisburg-Essen (Faculty of Chemistry) and Prof. Dr. Pham Hung Viet from VNU University of Science, KLATEFOS, as the program chairs.

Highlights of the analytica Vietnam 2023 conference included insightful panel discussions that brought together industry leaders, researchers, and decision makers to discuss the latest trends, challenges, and opportunities in the laboratory technology, analysis, and biotechnology sectors. The panel discussions delved into topics such as digitalization and automation in laboratories, advancements in precision medicine, sustainable solutions for environmental analysis, and the future of biotechnology in Southeast Asia.

Laboratory Tours

The pre-event laboratory tours allowed attendees to visit leading laboratories and research facilities in Ho Chi Minh City and gain first-hand insights into cutting-edge technologies and best practices. Participants were able to personally witness and gain the know-how into the procedure and technicalities of the laboratories in Vietnam, supported through the guided tour and allowing them to garner a deeper understanding of ASEAN research facilities.

Buyer-Seller Meeting Program

The buyer-seller programs went one step further to facilitate meaningful interactions between exhibitors and potential buyers, creating a conducive environment for business collaborations and partnerships. This edition saw the successful completion of 338 pre-arranged business meetings, reflecting a positive increasing trend from previous editions. On top of that, the networking nights and hosted buyer programs provided ample opportunities for participants to connect with fellow professionals, exchange ideas, and foster new business relationships. The event also witnessed the participation of high-level delegations from Laos, Cambodia and Vietnam, further enhancing regional cooperation and collaboration in the laboratory and biotechnology industries.

About Messe München GmbH

Messe München GmbH is one of the world’s leading trade fair organizers with more than 50 trade fairs for capital goods, consumer goods, and new technologies. Every year, Messe München organizes more than 200 events in Munich, Germany, and abroad, attracting over 30,000 exhibitors and 2 million visitors. The company’s mission is to create innovative, sustainable, and profitable platforms for its customers to do business and connect with their target markets.

analytica Vietnam

analytica Vietnam is the premier trade fair for laboratory technology, analysis, and biotechnology in Southeast Asia. Organized by Messe München, the event brings together industry professionals, researchers, and policymakers to showcase the latest technologies, exchange knowledge, and foster business collaborations. analytica Vietnam features an exhibition, conference, pre-event laboratory tours, buyer-seller programs, and networking opportunities, providing a comprehensive platform for the laboratory and biotechnology industries in the region. The upcoming edition is set to take place from April 2 to 4, 2025 at the SECC – Saigon Exhibition and Convention Center. More details can be found at https://www.analyticavietnam.com/.

analytica worldwide

Messe München is the world’s leading trade fair organizer for laboratory technology, analysis and biotechnology. The international network of exhibitions includes analytica, analytica China, analytica Anacon India & India Lab Expo, analytica Vietnam and analytica Lab Africa. Additional information about these exhibitions and their programs of events is available at http://www.analytica.de.

MMI Asia Pte Ltd

MMI Asia Pte. Ltd. was set up as the regional headquarter and a wholly owned subsidiary of Messe München in 1992. With subsidiaries in China and India, MMI Asia organizes trade fairs in China, India and ASEAN countries; promotes global trade expansion by facilitating participation of Asian exhibitors in Messe München fairs worldwide; it also provides consultancy in professional trade fair and conference management to government bodies, international trade and promotion organizations, and trade associations.

Contact:
MMI Asia Pte. Ltd.
Daniel Shi
Exhibition Director
Daniel@mmiasia.com.sg

analytica Vietnam 2023: The Largest Gathering of Laboratory Technology, Analysis and Biotechnology Professionals in Southeast Asia

The largest ever edition of analytica Vietnam, 10% outstanding increase in exhibition space with over 200 companies and brands with country pavilions from Germany, China and Singapore.
The three-day event will consist of exhibits, world-class conference, forum and tutorials, pre-event laboratory tour, buyer-seller program, networking night and hosted buyer delegations from Laos and Cambodia.
Registration to attend is FREE and open. Learn, network and reconnect with our confirmed exhibitors, international pavilions and key industry leaders.

The 7^th analytica Vietnam 2023 is set to take place from April 19-21, 2023, at the Saigon Exhibition and Convention Center in Ho Chi Minh City, Vietnam. The event is organized by Messe München, a leading international trade fair organizer, and is expected to attract thousands of exhibitors and visitors from around the world.

HANOI, Vietnam, Apr 5, 2023 – (ACN Newswire) – analytica Vietnam 2023 is a premier event for laboratory technology, analysis, and biotechnology professionals. The conference program features over 30 conference sessions and panel discussions presented by leading industry experts from across the globe. Attendees can expect to learn about the latest trends, challenges, and advancements in the industry, and gain insights into the future of laboratory technology and analysis.

analytica Vietnam, known as the most important hub in the ASEAN Region, is celebrating its biggest event ever with expected 5,000 diagnostic professionals, industry’s top buyers and investment decision-makers from more than 30 countries in the world. The trade fair will be the first face-to-face meeting since the hit of COVID-19. With sponsorships from Thermo Fisher, BIOVIA and BTG, the upcoming edition of analytica Vietnam 2023 is expected to bring together a spectacular reunion of the science and research sector.

The 2023 trade fair exhibitors include national and international industry giants – Thermo Fisher Scientific, Shimadzu, Merck, Leco, ITS, DKSH, 2H Instruments, Scilab, Eppendorf and Waters. The exhibition show will feature international exhibitors from – Germany, Italy, UK, Japan, Canada, Korea, France, Czech Republic, USA, Singapore, India, Thailand, and China. The German Federal Ministry for Economic Affairs and Climate Action and the Association of Small & Medium Enterprises Singapore (ASME) will support the exhibition with a German and Singapore Pavilion.

“We are thrilled to welcome the leading professionals and companies in the laboratory technology, analysis, and biotechnology industries to analytica Vietnam 2023,” said Mr. Michael Wilton, CEO & Managing Director of MMI Asia Pte Ltd, a subsidiary of Messe München GmbH. “This year’s event will provide attendees with unparalleled opportunities to network, learn, and discover the latest products and technologies in the industry.”

The Vietnamese government and Messe München are at the forefront of industry development in Vietnam. With analytica Vietnam, we offer the perfect platform to support the further development of the industry in the country, facilitate know-how transfer and promote investment in laboratory and biotechnology,” says Armin Wittmann, Project Manager at Messe München GmbH.

Apart from the exhibition area, analytica Vietnam 2023 offers valuable first-hand know how. The trade fair includes several side events such as a world-class conference, forum and tutorials, pre-event laboratory tours, buyer-seller program, networking night and hosted buyer program to offer visitors a holistic experience of current technologies and trending developments in the market.

Conference Program from top industry experts

The analytica Vietnam Conference will take place on 19-20 April in parallel to the with the trade fair. The conference program features over 30 conference lectures presented by national and international experts from science and research sector across the globe to report on the latest topics in the areas of biomedical, and forensic analysis, novel analytical methods, food analysis and environment analysis and quality control. It is organized by Prof. Dr. Oliver J. Schmitz (University of Duisburg-Essen, Faculty of Chemistry) and Prof. Dr. Pham Hung Viet (VNU University of Science, KLATEFOS).

Latest laboratory working practices

There will also be two practical tutorials on laboratory working practices on both days of the conference. The two half-day workshops “Compliant Modernization of HPLC Gradient Elution Methods in View of USP 621 Revision” and ” 3-MCPD and MOSH/MOAH Analysis” inform about the details of the automated workflows for routine analysis.” They focus on laboratory staff and students and require advance registration.

The Exhibitor Forum, part of supporting program within the exhibition halls, provides exhibitors with a platform for presenting their products and services live to a professional audience which is interested in the applicability of laboratory technology, analysis, biotechnology and diagnostics related services and products.

Various applications and marketable product innovation are to be demonstrated at the event include:

Comprehensive Testing & QC solutions from Farm to Fork – Thermo Fisher
R&D to Manufacturing – Connected Bio/Pharmaceutical Organization – Digital Continuity using 3DS platform – BIOVIA
Competence Cold Storage & Cell Cultivation Solutions through Innovation – Eppendorf Asia Pacific Sdn Bhd
Go beyond the limitation on environmental analysis using Agilent Technologies solutions – DKSH Vietnam
UV/VIS Spectrophotometer with EMC-Lambda Software and Audit Trail CFR 21 part 11 compliance – EMCLAB Instruments GmbH
A novel technology for DNA/RNA lab – Nippon Genetics Europe GmbH
Nitrogen determination according to Kjeldahl – behr Labor-Technik GmbH
Microplastic pollution: Analyse the problem and seek the solution with Bruker FT-IR spectroscopy – Bruker
Automatic Solution for Sample Preparation and Microbiological Analysis – Hoa Viet Co Ltd
LabWare LIMS – Labware
Amino Acid Analysis of Food – Hitachi High-Tech Scientific Solutions Co Ltd
Optimizing the production of probiotics and fermented products – TSI Hanoi
Participation in both the trade fair and supporting program is free of charge for visitors.

About Messe Muenchen GmbH

Messe Muenchen GmbH is one of the world’s leading trade fair organizers with more than 50 trade fairs for capital goods, consumer goods, and new technologies. Every year, Messe Muenchen organizes more than 200 events in Munich, Germany, and abroad, attracting over 30,000 exhibitors and 2 million visitors. The company’s mission is to create innovative, sustainable, and profitable platforms for its customers to do business and connect with their target markets.

analytica Vietnam

With its exhibition areas of laboratory technology, analysis, biotechnology and diagnostics, analytica Vietnam with the analytica Vietnam conference targets the growing market of Vietnam. 143 exhibitors and 4,144 visitors participated in analytica Vietnam 2019. The trade fair takes place every two years. The upcoming edition will take place from April 19 to 21, 2023 at the SECC – Saigon Exhibition and Convention Center. More details can be found at https://www.analyticavietnam.com/.

analytica worldwide

MMI Asia Pte Ltd

Press contact:
Syafia Naniesya (Nanie)
E: syafia@mmiasia.com.sg
T: +65 62360988
Marketing Executive
MMI Asia Pte Ltd

Avantor Named Best Bioprocessing Supplier in Cell and Gene Therapy at the Biopharma Excellence Awards India Edition

Award recognizes Avantor’s outstanding efforts to expand the market reach for life-altering innovative cell and gene therapies

Pune, INDIA, April 3, 2023 – (ACN Newswire) – Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, education and government, advanced technologies and applied materials industries, has been honored with the Best Bioprocessing Supplier Award for Cell and Gene Therapy at the Biopharma Excellence Awards (BEA) India Edition 2023, organized by IMAPAC in Pune, India.

Ganesh Bade – Head of Biopharma India Middle East & Africa (IMEA), Avantor (right) receiving the accolade at the Awards ceremony.

The award recognizes Avantor’s outstanding efforts to support the expansion of life-altering innovative cell and gene therapies to treat complex disease. Avantor is focused on making valuable contributions to cell and gene therapy production and offers expertise, technology capabilities and commitment to providing solutions. Recently, Avantor was also accorded the Best Bioprocessing Company in Chromatography at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2023 held in Singapore.

Ganesh Bade, Head Biopharma India Middle East and Africa (IMEA) at Avantor, said, “Cell and gene therapy is considered a game-changer for the biopharma industry. But the real effort lies in supplying this life altering solution at a reasonable cost to those in need. With high purity production chemicals, sterile fluid transfer systems, cell culture components and excipient technologies, Avantor is advancing the scalability and manufacturability of viral vector production to cell and gene therapies.”

“One of the most revolutionary modalities rising in the biopharmaceutical sector is cell and gene therapies. Avantor offers a comprehensive range of bioprocessing solutions such as media and supplements, single-use technologies, and custom development services to help accelerate the development and commercialization of cell and gene therapies,” said Amit Sehgal, Managing Director, Avantor India. “With this award, we are renewing our commitment to make cell and gene therapy successful and supply it with greater efficacy and reduced risk.”

Avantor provides compliant materials in scalable formats and single-use solutions for viral vector, CAR-T and gene therapies manufacturing, that have the potential to help reduce contamination risk, improve resource efficiency and reduce labor and energy costs. As part of its regulatory support services, Avantor also helps customers navigate the complex regulatory landscape of cell and gene therapy development and commercialization.

The Best Bioprocessing Supplier in Chromatography award recognizes Avantor’s ongoing efforts to provide innovative chromatography solutions that enable biopharmaceutical manufacturers to optimize processes and enhance product quality. With over four decades of experience in bioprocessing, Avantor is committed to addressing the complex challenges of downstream chromatography by providing a comprehensive range of equipment, products and services.

About Avantor

About Bioprocessing Excellence Awards (ABEA) India Edition 2023

The Biopharma Excellence Awards (BEA) India 2023 seeks to recognize exceptional biologics and vaccine experts, organizations and technologies that facilitate vaccine R&D and biologics manufacturing excellence at enhanced speed, reduced cost and superior quality. The BEA India Edition 2023 applauds extraordinary leaders & trendsetters of today and inspires the innovators of tomorrow.

Regional Media Contact:
Christina Koh
Director, Communications – AMEA
Avantor
M: +65 9720 0169
Christina.Koh@avantorsciences.com

Earable Neuroscience and Excelpoint Announces Strategic Partnership to Accelerate the Commercialisation of the World’s First AI-powered Consumer Wearable, FRENZ Brainband, to Solve Global Sleep Pandemic

Since the COVID-19 pandemic began, researchers around the world have documented a surge in sleep disorders which affect overall health, safety and quality of life
Invented by Earable® Neuroscience, FRENZ™ Brainband is the world’s first AI-powered consumer wearable that tracks and stimulates brain activities to enhance mental well-being through improvements in sleep, relaxation and focus
With its leading regional B2B business platform that provides quality electronics components with integrated R&D capabilities, Excelpoint will be the exclusive procurement partner for the electronics components used for the production of FRENZ™ Brainband
At the same time, PlanetSpark, the entrepreneurial and strategic investment arm of Excelpoint, is currently exploring its options to make an investment in Earable® Neuroscience

Singapore / Boulder, CO, Mar 31, 2023 – (ACN Newswire) – Earable® Neuroscience U.S. (“Earable®“), is pleased to announce a strategic partnership with Singapore-based Excelpoint Technology Pte. Ltd., (“Excelpoint“) to accelerate the commercialisation of the world’s first AI-powered consumer wearable, FRENZ™ Brainband, which tracks and stimulates brain activities to enhance mental well-being through improvements in sleep, relaxation and focus.

Mr. Tam Vu – CEO of Earable Neuroscience U.S. on the left, and Mr. Albert Phuay – Chairman of Excelpoint on the right – shared their visions in making positive impacts for human wellbeing.

The Strategic Agreement Signing Ceremony was presented by the leadership team from Earable Neuroscience U.S. and Excelpoint under the witness of the strategic partner – Analog Devices

FRENZ™ Brainband can precisely tracks vital data points in real-time, provides instant personalized feedback with cognitive behavioral therapy content via the integrated bone-conduction speakers, and leverages AI and machine learning algorithms to continuously evolve and provide meaningful insights to enhance mental well-being for individuals.

Since the COVID-19 pandemic began, researchers around the world have documented a surge in sleep disorders which affect overall health, safety and quality of life.

Powered by proprietary technologies, FRENZ™ Brainband is an invention of Earable® Neuroscience, founded by Dr Tam Vu, a scientist and professor with lifelong research in neuroscience and computer science, is a deep tech company focused on delivering scalable, human-centric neuroscience solutions that improve the everyday experience — from deep sleep to all-day focus.

With eight years of intensive deep tech R&D by scientists from the University of Colorado Boulder and University of Oxford, FRENZ™ Brainband holds 15 global patents in machine learning algorithms, materials science, and electrical engineering. FRENZ™ Brainband has been accorded multiple awards in various international technology and design competitions, marking its position as the world’s first AI-powered consumer head wearable dedicated for improving quality of sleep and cognitive functions.

Singapore-based Excelpoint was established in 1987 and it has grown into a leading regional electronics components distributor providing quality electronic components from leading electronics group such as ADI, Xilinx, NXP, Samsung, Qualcomm, Panasonic, Fujitsu, TDK, and Epson, among others as well as engineering design services and supply chain management to original equipment manufacturers (“OEMs”), ODMs and electronics manufacturing services (“EMS”) in the Asia Pacific region. Excelpoint is also the authorised distributor of Qualcomm in ASEAN, India, Australia and New Zealand.

Strategic Partnership of Earable® Neuroscience and Excelpoint to Accelerate the Commercialisation of FRENZ™ Brainband

Combined with its neuroscience data platform, Earable® Neuroscience is at the final stage of commercialisingFRENZ™ Brainband.

The main goal of the strategic partnership between Earable® Neuroscience and Excelpoint is for both companies to leverage on each other’s capabilities and networks to accelerate the commericalisation of FRENZ™ Brainband, thereby enabling an entirely new world of possibilities for neuroscience applications.

As part of the strategic partnership, Excelpoint will be the exclusive procurement partner for the electronics components used for the production of FRENZ™ Brainband. In addition, Excelpoint will provide favorable procurement terms to support Earable® Neuroscience so as to accelerate the commercialisation phase of FRENZ™ Brainband.

At the same time, PlanetSpark Pte. Ltd., (“PlanetSpark”) the entrepreneurial and strategic investment arm of Excelpoint, is currently exploring its options to make an investment in Earable® Neuroscience.

Commenting on the strategic partnership, Dr. Tam Vu, Founder and CEO of Earable® Neuroscience, said: “Earable® Neuroscience’s vision is to make the daily benefits of neuroscience accessible to billions of people to enhance their cognitive functions and unlock the brain’s potential, improving productivity, mental wellbeing, and quality of life.

Excelpoint’s global expertise and ecosystem in electronic components and supply chain management makes them the ideal partner to help us to secure the scalability of this vision.”

Mr. Albert Phuay, Chairman of Excelpoint added, “We share Earable® Neuroscience aspirations to drive innovation in the field of disruptive sleeptech and we are thrilled with this partnership to accelerate the commercialisation of FRENZ™ Brainband to new levels of growth and expansion.

We believe that Earable®’s advanced neuroscience expertise, combined with our ecosystem will enable us to scale up the production of high-quality and cutting-edge sleeptech products that make a meaningful impact in the lives of people around the world.“

About Earable® Neuroscience U.S.:

Earable® Neuroscience U.S. is a deep tech company building an applied neuroscience ecosystem to improve the everyday experience. Earable® Neuroscience invented the FRENZ™ Brainband – the world’s first AI-powered consumer wearable that can precisely track and stimulate brain activity for better sleep, focus, and relaxation. FRENZ™ holds multiple scientific awards and 15 global patents and patents pending.

MSRP Price is $490. Pre-order now available at www.frenzband.com

Media Contact: media@earable.ai

About Excelpoint:

Excelpoint is a leading regional electronics components distributor providing quality electronic components, engineering design services and supply chain management to original equipment manufacturers (“OEMs“), ODMs and electronics manufacturing services (“EMS“) in the Asia Pacific region. Established in 1987 and headquartered in Singapore, Excelpoint’s business presence spans more than 10 countries across Asia Pacific with a workforce of more than 700 people from different nationalities and cultural backgrounds. For more information on Excelpoint, please visit www.excelpoint.com

Media Contact: Ms Phuay Li Ying
Head, Corporate Development
Direct: +65 6210 6649
Mobile: +65 9688 8898
Email: phuay.li.ying@excelpoint.com.sg